Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osama A Amin

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
BMC Cardiovascular Disorders|November 20, 2020
The safety of Ramadan Fasting following Percutaneous Coronary InterventionOsama A Amin, Ahmed Alaarag
Anatolian Journal of Cardiology|March 10, 2021
The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fractionOsama A Amin, Ahmed F Alaarag
Orthopedics|November 12, 2009
Arthrodiatasis for the treatment of Perthes' diseaseTarek A Aly, Osama A Amin
Journal of the Saudi Heart Association|February 21, 2025
The Safety of Ramadan Fasting in Chronic Heart Failure Patients With Reduced Ejection FractionAhmed F Alaarag, Mahmoud A Elkhalek Abou-Omar, Osama A Amin
Cardiology and Therapy|October 25, 2024
ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP FoundationMohamed Sobhy, Adel Eletriby, Hany Ragy, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
BMC Cardiovascular Disorders|November 20, 2020
The safety of Ramadan Fasting following Percutaneous Coronary InterventionOsama A Amin, Ahmed Alaarag
Anatolian Journal of Cardiology|March 10, 2021
The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fractionOsama A Amin, Ahmed F Alaarag
Orthopedics|November 12, 2009
Arthrodiatasis for the treatment of Perthes' diseaseTarek A Aly, Osama A Amin
Journal of the Saudi Heart Association|February 21, 2025
The Safety of Ramadan Fasting in Chronic Heart Failure Patients With Reduced Ejection FractionAhmed F Alaarag, Mahmoud A Elkhalek Abou-Omar, Osama A Amin
Cardiology and Therapy|October 25, 2024
ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP FoundationMohamed Sobhy, Adel Eletriby, Hany Ragy, et al.
Pageof 1